SCHEDULE: Nantahala Capital Boosts Grace Therapeutics Stake

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 6.75% of Grace Therapeutics, Inc. common stock as of June 30, 2026.

Summary

• Nantahala Capital Management, LLC, and its managing members Wilmot B. Harkey and Daniel Mack, have filed a Schedule 13G, indicating their beneficial ownership of Grace Therapeutics, Inc. common stock.
• As of June 30, 2026, the reporting persons collectively hold 1,178,203 shares, representing 6.75% of the outstanding common stock.
• This ownership stake includes shares that may be acquired within sixty days through the exercise of convertible securities.
• Nantahala Capital Management is identified as an investment adviser, and Messrs. Harkey and Mack are identified as control persons of Nantahala.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, indicating significant institutional ownership and a potential for increased investor confidence due to the substantial stake held by Nantahala Capital Management.

Positives

• Significant institutional ownership by Nantahala Capital Management, LLC, suggests confidence in Grace Therapeutics' long-term prospects.
• The 6.75% stake represents a substantial investment, potentially signaling a stable or growing investor base.
• The filing indicates that the shares were acquired and are held in the ordinary course of business, not for the purpose of influencing control.

Negatives

• The filing does not disclose any negative financial performance or operational issues.
• No specific details are provided regarding the convertible securities, which could represent future dilution if exercised.

Risks

• The potential exercise of convertible securities could lead to dilution of existing shareholders' stakes.
• As with any investment, market volatility and company-specific performance risks remain.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from the company. However, the acquisition of shares through convertible securities implies a future potential increase in ownership.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that significant stake acquisitions by investment management firms like Nantahala Capital are common in the biotechnology and therapeutics sector, often signaling a belief in the company's pipeline or market potential.

Stakeholder Impact

• Shareholders may see increased stability in the stock price due to significant institutional backing.
• Potential for increased scrutiny on company performance from a substantial investor.

Next Steps

• Nantahala Capital Management may exercise convertible securities within sixty days, potentially increasing their ownership stake.
• Continued monitoring of Grace Therapeutics' performance and any further filings by Nantahala Capital.

Key Dates

Keywords

Grace Therapeutics, Nantahala Capital Management, Schedule 13G, Beneficial Ownership, Investment Adviser, Convertible Securities, Institutional Investor